Literature DB >> 7087894

Tissue disposition of doxorubicin in experimental animals.

Y T Lee, K K Chan, P A Harris.   

Abstract

Doxorubicin was administered via peripheral vein to rabbits with or without VX-2 carcinoma and to rats with 13762 mammary adenocarcinoma. In rabbits, the doxorubicin tissue levels showed a decreasing order as follows: kidney, spleen, lung, heart, marrow, liver, gut, tumor, muscle, and fat. In rats, the order of doxorubicin concentration in organs from high to low appeared similar, except lung concentration was closer to spleen and kidney; and doxorubicin level in fat was higher than that in muscle. When different doses of doxorubicin were given, the tissue concentrations were proportional to the dose. At 24 hr after administration, the concentration of doxorubicin in liver was much higher in rats that received the drug injected directly into the hepatic artery or mesenteric-portal vein than in those that received the drug via the peripheral vein. In the discussions, our results in rats and rabbits were compared with what had been reported in the literature of tissue uptake studies in mice, dogs, and patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7087894     DOI: 10.1002/mpo.2950100306

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  9 in total

1.  The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.

Authors:  Zuyue Sun; Jill Schriewer; Mingxin Tang; Jerry Marlin; Frederick Taylor; Ralph V Shohet; Eugene A Konorev
Journal:  J Mol Cell Cardiol       Date:  2015-12-11       Impact factor: 5.000

2.  Late congestive heart failure after hematopoietic cell transplantation.

Authors:  Saro H Armenian; Can-Lan Sun; Liton Francisco; Julia Steinberger; Seira Kurian; F Lennie Wong; Jon Sharp; Richard Sposto; Stephen J Forman; Smita Bhatia
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation.

Authors:  Saro H Armenian; Can-Lan Sun; Tabitha Shannon; George Mills; Liton Francisco; Kalyanasundaram Venkataraman; F Lennie Wong; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2011-10-05       Impact factor: 22.113

4.  Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats.

Authors:  C S Hughes; S L Vaden; C A Manaugh; G S Price; L C Hudson
Journal:  J Neurooncol       Date:  1998-03       Impact factor: 4.130

Review 5.  Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.

Authors:  Rachel E Nicoletto; Clyde M Ofner
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-12       Impact factor: 3.333

6.  Doxorubicin concentration time course in the myocardium after single administration to the dog. Possible role in the cardiac effects.

Authors:  Q Timour; P Nony; J Lang; M Lakhal; V Trillet; G Faucon
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Doxorubicin concentrations in plasma and myocardium and their respective roles in cardiotoxicity.

Authors:  Q Timour; P Nony; J Lang; M Lakhal; V Trillet; G Faucon
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

8.  Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.

Authors:  Saro H Armenian; Yan Ding; George Mills; Canlan Sun; Kalyanasundaram Venkataraman; Florence Lennie Wong; Susan L Neuhausen; David Senitzer; Shirong Wang; Stephen J Forman; Smita Bhatia
Journal:  Br J Haematol       Date:  2013-08-08       Impact factor: 6.998

Review 9.  Cardiovascular disease in survivors of hematopoietic cell transplantation.

Authors:  Saro H Armenian; Eric J Chow
Journal:  Cancer       Date:  2013-10-25       Impact factor: 6.860

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.